Laura L. Douglass Sells 10,000 Shares of La Jolla Pharmaceutical (LJPC) Stock
La Jolla Pharmaceutical (NASDAQ:LJPC) Director Laura L. Douglass sold 10,000 shares of the business’s stock in a transaction on Saturday, December 29th. The stock was sold at an average price of $32.32, for a total value of $323,200.00. Following the sale, the director now directly owns 6,000 shares in the company, valued at $193,920. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
La Jolla Pharmaceutical (NASDAQ LJPC) traded up $0.68 during trading hours on Wednesday, reaching $33.85. The company had a trading volume of 409,334 shares, compared to its average volume of 594,634. The firm has a market capitalization of $749.62, a price-to-earnings ratio of -6.64 and a beta of 1.63. La Jolla Pharmaceutical has a 52-week low of $16.71 and a 52-week high of $39.28.
La Jolla Pharmaceutical (NASDAQ:LJPC) last issued its earnings results on Thursday, October 26th. The biopharmaceutical company reported ($1.19) earnings per share for the quarter, topping the consensus estimate of ($1.24) by $0.05. sell-side analysts predict that La Jolla Pharmaceutical will post -4.91 EPS for the current year.
Several research analysts recently weighed in on the company. Cowen reissued a “buy” rating and set a $55.00 price target on shares of La Jolla Pharmaceutical in a research report on Friday, October 27th. ValuEngine raised La Jolla Pharmaceutical from a “strong sell” rating to a “sell” rating in a research report on Tuesday, December 26th. SunTrust Banks set a $65.00 price target on La Jolla Pharmaceutical and gave the company a “buy” rating in a research report on Thursday, December 28th. Zacks Investment Research raised La Jolla Pharmaceutical from a “hold” rating to a “buy” rating and set a $39.00 price target on the stock in a research report on Wednesday, November 1st. Finally, Jefferies Group reissued a “buy” rating and set a $40.00 price target on shares of La Jolla Pharmaceutical in a research report on Tuesday, October 3rd. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and seven have issued a buy rating to the stock. The company has an average rating of “Buy” and an average price target of $57.14.
La Jolla Pharmaceutical Company Profile
La Jolla Pharmaceutical Company is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies to improve outcomes in patients suffering from life-threatening diseases. LJPC-501 is its formulation of angiotensin II for the potential treatment of catecholamine-resistant hypotension (CRH).
Receive News & Ratings for La Jolla Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for La Jolla Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.